Search the Studies

78 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001599-CPhase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)Recruitment has not started18-120 YearsNCI Leukemia Lymphocytic
001524-CA Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell MalignanciesParticipants currently recruited/enrolled18-75 YearsNCI Leukemia Lymphocytic
000923-HObservational Study of Cardiac Arrhythmias During Treatment with BTK Inhibitors or VenetoclaxParticipants currently recruited/enrolled18-110 YearsNHLBILeukemia Lymphocytic
000444-HVaccine Responses in Patients with B Cell MalignanciesParticipants currently recruited/enrolled18-90 YearsNHLBILeukemia Lymphocytic
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBILeukemia Lymphocytic
000324-CPhase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-35 YearsNCI Leukemia Lymphocytic
20-H-0016Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Completed Study; data analyses ongoing18-125 YearsNHLBILeukemia Lymphocytic
20-C-0162A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesNo longer recruiting/follow-up only18-125 YearsNCI Leukemia Lymphocytic
19-H-0111Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)Participants currently recruited/enrolled18-125 YearsNHLBILeukemia Lymphocytic
19-H-0001Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) TherapyCompleted Study; data analyses ongoing18-100 YearsNHLBILeukemia Lymphocytic
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Leukemia Lymphocytic
17-H-0118A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-100 YearsNHLBILeukemia Lymphocytic
15-H-0172A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBILeukemia Lymphocytic
15-H-0016A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.No longer recruiting/follow-up only18-125 YearsNHLBILeukemia Lymphocytic
15-C-0093Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCTParticipants currently recruited/enrolled3-35 YearsNCI Leukemia Lymphocytic
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesNo longer recruiting/follow-up only3-39 YearsNCI Leukemia Lymphocytic
14-C-0004A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia Lymphocytic
12-H-0035A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p DeletionNo longer recruiting/follow-up only18-125 YearsNHLBILeukemia Lymphocytic
11-C-0136Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging EvaluationCompleted Study; data analyses ongoing2-120 YearsNCI Leukemia Lymphocytic
10-H-0141A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Completed Study; data analyses ongoing18-99 YearsNHLBILeukemia Lymphocytic
10-C-0066A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer TreatmentParticipants currently recruited/enrolled18-125 YearsNCI Leukemia Lymphocytic
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationCompleted Study; data analyses ongoing18-75 YearsNCI Leukemia Lymphocytic
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBILeukemia Lymphocytic
08-H-0105Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)Participants currently recruited/enrolled18-110 YearsNHLBILeukemia Lymphocytic
06-H-0190Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)Completed Study; data analyses ongoing18-85 YearsNHLBILeukemia Lymphocytic
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation1-75 YearsNCI Leukemia Lymphocytic
02-C-0210Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyNo longer recruiting/follow-up only0-125 YearsNCI Leukemia Lymphocytic
001784-CPhase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell TransplantationRecruitment has not started18-120 YearsNCI Leukemia
001620-CPilot Prospective Study for PET-CT Imaging in Participants with Relapsed/Refractory Acute LeukemiasParticipants currently recruited/enrolled5-39 YearsNCI Leukemia
001554-CPhase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitment has not started12-120 YearsNCI Leukemia
001541-CA Phase I/II Trial of Eltanexor (KPT-8602) with Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesParticipants currently recruited/enrolled18-120 YearsNCI Leukemia
000975-CCollection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
000867-CCHumanitarian Use Device (HUD) Protocol for Use of Miltenyi CliniMACS (Registered Trademark) CD34 Reagent System in AMLParticipants currently recruited/enrolled0-125 YearsCC Leukemia
000792-CA Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic LeukemiaParticipants currently recruited/enrolled1-25 YearsNCI Leukemia
000732-CA Long-Term Follow-Up Study of Patients Who Received VOR33Participants currently recruited/enrolled18-125 YearsNCI Leukemia
000731-CA First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-70 YearsNCI Leukemia
000661-CComprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)Participants currently recruited/enrolled0-120 YearsNCI Leukemia
000631-CInvestigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell TherapyClinical hold/Recruitment or enrollment suspended5-125 YearsNCI Leukemia
000613-CPhase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood StParticipants currently recruited/enrolled12-125 YearsNCI Leukemia
000509-CAn Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to BEnrolling by Invitation18-125 YearsNCI Leukemia
000489-CPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Leukemia
000464-HEvaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative TherapiesEnrolling by Invitation4-125 YearsNHLBILeukemia
000115-CA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster DCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyCompleted Study; data analyses ongoing2-125 YearsNCI Leukemia
21-C-0019Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0076Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCLParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0075Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI Leukemia
20-C-0011Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
19-HG-0059Longitudinal Studies of Patients and Families with Familial Platelet Disorders with Associated Myeloid Malignancy (FPDMM) Caused by RUNX1 Germline Variants or FPDMM-Like ConditionsParticipants currently recruited/enrolled0-125 YearsNHGRILeukemia
19-C-0112Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic MalignanciesParticipants currently recruited/enrolled12-120 YearsNCI Leukemia
19-C-0042A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Leukemia
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Leukemia
17-C-0028A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic LeukemiaCompleted Study; data analyses ongoing2-21 YearsNCI Leukemia
16-C-0061Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsParticipants currently recruited/enrolled18-120 YearsNCI Leukemia
15-C-0141Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell StudiesEnrolling by Invitation18-125 YearsNCI Leukemia
15-C-0067A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
13-I-0157The Natural History of GATA2 Deficiency and Related DisordersParticipants currently recruited/enrolled2-100 YearsNIAIDLeukemia
13-H-0116A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult PatientsParticipants currently recruited/enrolled4-125 YearsNHLBILeukemia
13-C-0132Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC SyndromeParticipants currently recruited/enrolled8-70 YearsNCI Leukemia
12-C-0193Lymphoid Malignancies and Precursors: Tissue Acquisition ProtocolParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
12-C-0160Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their ParentsCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
11-I-0007Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined ImmunodeficiencyParticipants currently recruited/enrolled2-40 YearsNIAIDLeukemia
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Leukemia
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
10-C-0025Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
09-C-0053Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow DonEnrolling by Invitation1-125 YearsNCI Leukemia
09-C-0005Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual DiseaseNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
07-C-0195Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the TreaCompleted Study; data analyses ongoing18-74 YearsNCI Leukemia
05-H-0130Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell TransplantsParticipants currently recruited/enrolled7-80 YearsNHLBILeukemia
02-I-0286Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeParticipants currently recruited/enrolled2-125 YearsNIAIDLeukemia
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-100 YearsNHLBILeukemia
99-H-0050Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic DiseasesCompleted Study; data analyses ongoing2-80 YearsNHLBILeukemia
98-N-0047Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)Participants currently recruited/enrolled18-120 YearsNINDSLeukemia
96-H-0049Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic TransplantationParticipants currently recruited/enrolled18-60 YearsNHLBILeukemia
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisParticipants currently recruited/enrolled12-125 YearsNCI Leukemia